The pipeline of next-generation treatments is advancing rapidly: Novo Nordisks CagriSema, a fixed-dose combination of semaglutide and the amylin analogue cagrilintide, has an FDA decision expected in late 2026 and could further accelerate the market
5.16 RNA isolation, reverse transcription and quantitative real-time PCR For mRNA isolation from primary IEC or organoids, the NucleoSpin RNAII kit (Macherey-Nagel) was used according to the manufacturers instructions
She has a Bachelors of Science in Biomedical Science from Oakland University in Auburn Hills, Michigan
(link to article in the comments) #GLP1s #WeightLossDrugs #EmployeeBenefits To view or add a comment, sign in 27% of employers say GLP-1 weight-loss drugs made up more than 15% of their total annual claims in 2024
Microdosing can deliver comparable outcomes to regular dosing, particularly for individuals focusing on gradual and sustainable weight loss, as well as enhanced metabolic health